中国抗体-B（03681.HK）今日盘中大涨14.45%，引发市场关注。该股价的强劲表现是在香港医药股整体走强的背景下发生的，反映出投资者对医药行业的持续看好。
除中国抗体-B外，多只医药股今日也呈现上涨态势。其中，维立志博-B（09887.HK）作为新股首日挂牌，涨幅一度扩大至120%以上，表现尤为亮眼。此外，乐普生物-B（02157.HK）上涨3%，同源康医药-B（02410.HK）上涨4%，显示医药板块整体受到资金青睐。
医药股的集体走强可能与行业整体前景向好以及新股维立志博的热烈追捧有关。据悉，维立志博在公开发售阶段获得3494.78倍超额认购，国际配售阶段也获得40.78倍认购，反映出投资者对医药行业的高度关注和信心。这种积极情绪可能延续到其他医药股，推动整个板块走强，其中中国抗体-B作为行业重要代表之一，获得了显著的股价提升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.